Living-Donor Uterus Transplantation: A Clinical Review.

Mayer–Rokitansky–Küster–Hauser syndrome deceased donor hysterectomy laparoscopic live births robotic

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
29 Jan 2024
Historique:
received: 03 01 2024
revised: 22 01 2024
accepted: 27 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

Uterus transplantation (UTx) is currently the only available treatment for absolute uterine factor infertility. More than 90 uterus transplantations have been performed worldwide, mostly from living donors. Living-donor (LD) UTx is a challenging surgical procedure since it poses ethical issues, and it is a high-risk and invasive surgery with higher hysterectomy-related risks compared to conventional hysterectomy. A total of 59 living-donor hysterectomies have been reported in the literature, including 35 performed with a laparotomic approach, 20 with a robotic approach and 4 with a laparoscopic approach. The mean donor age was 45.6 ± 9.1 years, and 22 were unrelated with the recipients, 34 were emotionally related (27 mothers, 5 sisters, 2 mother's sisters). The mean recipient age was 28.8 ± 4.5 years. Mayer-Rokitansky-Küster-Hauser syndrome was the most common indication for uterus transplant. Robotic living-donor hysterectomy had the longest operative time but resulted in a lower blood loss and postoperative stay compared to laparotomic and laparoscopic approaches. Twenty-nine births from LD-UTx have been reported, four after robotic living-donor hysterectomy and twenty-five after a laparotomic procedure. UTx is now an effective treatment for women with UFI. While living-donor UTx in some cases may be considered an experimental procedure, it offers the extraordinary possibility to give women the opportunity to have a pregnancy. Many efforts should be made to reduce the potential risks for donors, including the use of mini-invasive techniques, and the efficacy of UTx in the recipients, giving the potential harm of immunosuppression in a recipient of a non-life-saving organ.

Identifiants

pubmed: 38337468
pii: jcm13030775
doi: 10.3390/jcm13030775
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Massimiliano Veroux (M)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Paolo Scollo (P)

Maternal and Child Department, Obstetrics and Gynecology, Cannizzaro Hospital, 95123 Catania, Italy.

Martina Maria Giambra (MM)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Giuseppe Roscitano (G)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Alessia Giaquinta (A)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Francesco Setacci (F)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Pierfrancesco Veroux (P)

Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95123 Catania, Italy.

Classifications MeSH